Moreover, a startup needs to be at the age of 11-15 years to get the investment from the fund. Among the most successful fund investment fields, there are Medical Device, Therapeutics. Among the most popular portfolio startups of the fund, we may highlight iSTAR Medical, Xeltis. The fund has specific favorite in a number of founders of portfolio startups.
The standard case for the fund is to invest in rounds with 4 partakers. Despite the LSP, startups are often financed by VI Partners AG, Life Sciences Partners, Kurma Partners. The meaningful sponsors for the fund in investment in the same round are SFPI-FPIM, S.R.I.W., Gimv.
The top activity for fund was in 2019. Deals in the range of 10 - 50 millions dollars are the general things for fund. The fund is constantly included in 2-6 deals per year.
Related Funds
| Fund Name | Location |
| 301 Ventures | College Park, Maryland, United States |
| AWI Ventures | Australia, New South Wales, Sydney |
| AZURE PLUS | Chiyoda, Japan |
| Chengdu High-tech Zone Venture Angel Fund | Chengdu, China, Sichuan |
| CICC Healthcare Investment Fund | Beijing, Beijing, China |
| Family and Friends Investment | - |
| Flywheel Ventures | New Mexico, Santa Fe, United States |
| Grey | New York, New York, United States |
| Henley Ventures | British Columbia, Canada, Surrey |
| Highlander Venture Fund | - |
| Huilun Biological Technology | China, Shanghai |
| Massachusetts Office of International Trade and Investment (MOITI) | - |
| Mayham Holding AG | - |
| Mike Egan | - |
| Providence St. Joseph Health | Renton, United States, Washington |
| Sapphire Capital Partners | England, London, United Kingdom |
| Spire Capital | New York, New York, United States |
| Tempus Partners | Australia, New South Wales, Sydney |
| Zhejiang Changxing Economic and Technological Development | China, Huzhou, Zhejiang |
| ZTE | China, Guangdong, Shenzhen |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
eTheRNA immunotherapies | $40M | 16 Jun 2020 | Belgium, Brussels-Capital | ||
iSTAR Medical | $47M | 05 Sep 2019 | Belgium, Antwerp, Belgium | ||
Amolyt Pharma | $79M | 31 Jul 2019 | Écully, Rhone-Alpes, France |
– Amolyt Pharma from Lyon develops therapeutic peptides for rare endocrine and related diseases.
– The company closed an $80m Series B round.
– The round was co-led by Sectoral Asset Management and Andera Partners, with participation from ATEM Capital, LSP, Novo Holdings (Novo Ventures), Kurma Partners, Mass General Brigham Ventures, Innobio 2 managed by Bpifrance, Orbimed, Pontifax, Eurazeo, Sham Innovation Santé/Turenne Capital and Credit Agricole Creation.
– The company plans to use the proceeds from the financing to advance its pipeline of potential therapeutics for rare endocrine and related diseases, including clinical development of AZP-3601 for hypoparathyroidism, pre-clinical development of AZP-3813 for acromegaly and ongoing research related to AZP-3404, and to further expand its early-stage pipeline through both internal research and development activities and potential in-licensing opportunities.
– Amolyt Pharma from Lyon develops therapeutic peptides for rare endocrine and related diseases.
– The company closed an $80m Series B round.
– The round was co-led by Sectoral Asset Management and Andera Partners, with participation from ATEM Capital, LSP, Novo Holdings (Novo Ventures), Kurma Partners, Mass General Brigham Ventures, Innobio 2 managed by Bpifrance, Orbimed, Pontifax, Eurazeo, Sham Innovation Santé/Turenne Capital and Credit Agricole Creation.
– The company plans to use the proceeds from the financing to advance its pipeline of potential therapeutics for rare endocrine and related diseases, including clinical development of AZP-3601 for hypoparathyroidism, pre-clinical development of AZP-3813 for acromegaly and ongoing research related to AZP-3404, and to further expand its early-stage pipeline through both internal research and development activities and potential in-licensing opportunities.
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
eTheRNA immunotherapies | $40M | 16 Jun 2020 | Belgium, Brussels-Capital | ||
iSTAR Medical | $47M | 05 Sep 2019 | Belgium, Antwerp, Belgium | ||
Amolyt Pharma | $79M | 31 Jul 2019 | Écully, Rhone-Alpes, France |
